Genenta Science (NASDAQ:GNTA - Get Free Report)'s stock had its "sell (e+)" rating reaffirmed by research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.
Genenta Science Trading Up 0.5%
Genenta Science stock opened at $3.18 on Wednesday. Genenta Science has a 52-week low of $2.56 and a 52-week high of $7.28. The company's 50 day moving average is $3.40 and its two-hundred day moving average is $3.73.
Institutional Investors Weigh In On Genenta Science
A number of large investors have recently modified their holdings of the company. Allianz SE increased its position in shares of Genenta Science by 126.2% in the 1st quarter. Allianz SE now owns 233,550 shares of the company's stock valued at $927,000 after purchasing an additional 130,300 shares during the last quarter. Algebris UK Ltd increased its position in shares of Genenta Science by 122.2% in the 1st quarter. Algebris UK Ltd now owns 100,000 shares of the company's stock valued at $368,000 after purchasing an additional 55,000 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of Genenta Science in the 4th quarter valued at approximately $46,000. 15.13% of the stock is owned by hedge funds and other institutional investors.
Genenta Science Company Profile
(
Get Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
